These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21069319)

  • 1. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.
    Kendziorra K; Wolf H; Meyer PM; Barthel H; Hesse S; Becker GA; Luthardt J; Schildan A; Patt M; Sorger D; Seese A; Gertz HJ; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):515-25. PubMed ID: 21069319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Sabri O; Meyer PM; Gräf S; Hesse S; Wilke S; Becker GA; Rullmann M; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Tiepolt S; Fischer S; Deuther-Conrad W; Hegerl U; Barthel H; Schönknecht P; Brust P
    Brain; 2018 Jun; 141(6):1840-1854. PubMed ID: 29672680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease.
    Meyer PM; Strecker K; Kendziorra K; Becker G; Hesse S; Woelpl D; Hensel A; Patt M; Sorger D; Wegner F; Lobsien D; Barthel H; Brust P; Gertz HJ; Sabri O; Schwarz J
    Arch Gen Psychiatry; 2009 Aug; 66(8):866-77. PubMed ID: 19652126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholine receptors in dementia and mild cognitive impairment.
    Sabri O; Kendziorra K; Wolf H; Gertz HJ; Brust P
    Eur J Nucl Med Mol Imaging; 2008 Mar; 35 Suppl 1():S30-45. PubMed ID: 18228017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine.
    Sabri O; Becker GA; Meyer PM; Hesse S; Wilke S; Graef S; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Habermann B; Neuhaus P; Fischer S; Tiepolt S; Deuther-Conrad W; Barthel H; Schönknecht P; Brust P
    Neuroimage; 2015 Sep; 118():199-208. PubMed ID: 26037057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (+)-[
    Tiepolt S; Becker GA; Wilke S; Cecchin D; Rullmann M; Meyer PM; Barthel H; Hesse S; Patt M; Luthardt J; Wagenknecht G; Sattler B; Deuther-Conrad W; Ludwig FA; Fischer S; Gertz HJ; Smits R; Hoepping A; Steinbach J; Brust P; Sabri O
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):731-746. PubMed ID: 32935187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia.
    Brašić JR; Cascella N; Kumar A; Zhou Y; Hilton J; Raymont V; Crabb A; Guevara MR; Horti AG; Wong DF
    Synapse; 2012 Apr; 66(4):352-68. PubMed ID: 22169936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET Imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN, a radioligand with improved brain kinetics.
    Kuwabara H; Wong DF; Gao Y; Valentine H; Holt DP; Ravert HT; Dannals RF; Horti AG
    J Nucl Med; 2012 Jan; 53(1):121-9. PubMed ID: 22173841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.
    Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Saunder T; Young K; Smith CL; Welch J; Woodward M; Wesnes KA; Savage G; Rowe CC
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):79-91. PubMed ID: 18949462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinergic Receptor Binding in Alzheimer Disease and Healthy Aging: Assessment In Vivo with Positron Emission Tomography Imaging.
    Sultzer DL; Melrose RJ; Riskin-Jones H; Narvaez TA; Veliz J; Ando TK; Juarez KO; Harwood DG; Brody AL; Mandelkern MA
    Am J Geriatr Psychiatry; 2017 Apr; 25(4):342-353. PubMed ID: 28162919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer's Disease.
    Oboshi Y; Kikuchi M; Terada T; Yoshikawa E; Bunai T; Ouchi Y
    J Alzheimers Dis; 2016 May; 53(3):817-30. PubMed ID: 27258412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging.
    Sabbagh MN; Shah F; Reid RT; Sue L; Connor DJ; Peterson LK; Beach TG
    Arch Neurol; 2006 Dec; 63(12):1771-6. PubMed ID: 17172618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment.
    Mitsis EM; Reech KM; Bois F; Tamagnan GD; Macavoy MG; Seibyl JP; Staley JK; van Dyck CH
    J Nucl Med; 2009 Sep; 50(9):1455-63. PubMed ID: 19690024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease.
    Truchot L; Costes N; Zimmer L; Laurent B; Le Bars D; Thomas-Antérion C; Mercier B; Hermier M; Vighetto A; Krolak-Salmon P
    Neuroimage; 2008 Apr; 40(3):1251-6. PubMed ID: 18313943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A spatial covariance
    Colloby SJ; Field RH; Wyper DJ; O'Brien JT; Taylor JP
    Neurobiol Aging; 2016 Nov; 47():83-90. PubMed ID: 27565302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
    Doll F; Dolci L; Valette H; Hinnen F; Vaufrey F; Guenther I; Fuseau C; Coulon C; Bottlaender M; Crouzel C
    J Med Chem; 1999 Jun; 42(12):2251-9. PubMed ID: 10377231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380.
    Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Ellis KA; Tochon-Danguy HJ; Chan JG; O'keefe GJ; Bradley J; Savage G; Rowe CC
    Synapse; 2009 Sep; 63(9):752-63. PubMed ID: 19484724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive evaluation of nicotinic acetylcholine receptor availability in mouse brain using single-photon emission computed tomography with [(123)I]5IA.
    Matsuura Y; Ueda M; Higaki Y; Watanabe K; Habara S; Kamino S; Saji H; Enomoto S
    Nucl Med Biol; 2016 Jun; 43(6):372-8. PubMed ID: 27260778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease.
    Meyer PM; Tiepolt S; Barthel H; Hesse S; Sabri O
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):376-86. PubMed ID: 25387119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.